USP is seeking stakeholder input on the topic of Novel Excipients with a survey open until end-March.
This survey seeks to identify the views of stakeholders on the current state of innovation in excipients and if there is a link to current and future challenges in fulfilling public health needs.
This survey analysis will help to identify specific issues with using novel excipients in pharmaceutical development and innovation. The survey on novel excipients is the result of U.S. FDA (CDER) collaborating with USP to develop data from the pharmaceutical industry and other stakeholders to assess the need and importance of novel excipients.
IPEC Europe recommends its members to answer to this USP survey and share the link below within your company as well with others that have an interest in novel excipients and drug innovation.
Any information provided is treated as confidential and is not attributable to your company.
The survey will be available until end-March.